Skip to main content
SpringerLink
Log in

Synergistic combination of azithromycin and sulfadiazine for treatment of toxoplasmosis in mice

  • New Antimicrobial Agent
  • Published:
European Journal of Clinical Microbiology and Infectious Diseases Aims and scope Submit manuscript

Abstract

Experiments were performed in vivo in a mouse model of acute toxoplasmosis to evaluate the effectiveness of the combination azithromycin/sulfadiazine. Azithromycin alone or sulfadiazine alone, at doses that did not provide any protection against death due to toxoplasmosis, were remarkably and significantly synergistic against murine toxoplasmosis when administered in combination.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Haverkos HW Toxoplasmic encephalitis study group. Assessment of therapy for toxoplasmic encephalitis. American Journal of Medicine 1987, 82: 907–914.

    PubMed  Google Scholar 

  2. Dannemann BR, Israelski DM, Remington JS Treatment of toxoplasmic encephalitis with intravenous clindamycin. Archives of Internal Medicine 1988, 148: 2477–2482.

    PubMed  Google Scholar 

  3. Luft BJ, Remington JS AIDS commentary: toxoplasmic encephalitis. Journal of Infectious Diseases 1988, 157: 1–6.

    PubMed  Google Scholar 

  4. Luft BJ In vivo and in vitro activity of roxithromycin againstToxoplasma gondii in mice. European Journal of Clinical Microbiology 1987, 6: 479–481.

    PubMed  Google Scholar 

  5. Araujo FG, Guptill DR, Remington JS Azithromycin: a macrolide antibiotic with potent activity againstToxoplasma gondii. Antimicrobial Agents and Chemotherapy 1988, 32: 755–757.

    PubMed  Google Scholar 

  6. Chang HR, Pechere JC In vitro effects of four macrolides (roxithromycin, spiramycin, azithromycin [CP-62,993], and A-56268) onToxoplasma gondii. Antimicrobial Agents and Chemotherapy 1988, 32: 524–529.

    PubMed  Google Scholar 

  7. Hofflin JM, Remington JS In vivo synergism of roxithromycin (RU 965) and interferon againstToxoplasma gondii. Antimicrobial Agents and Chemotherapy 1987, 31: 346–348.

    PubMed  Google Scholar 

  8. Araujo FG, Shepard RM, Remington JS In vivo activity of the macrolide antibiotics azithromycin, roxithromycin, and spiramycin againstToxoplasma gondii. European Journal of Clinical Microbiology and Infectious Disease 1991, 10: 519–524.

    Google Scholar 

  9. Gladue RP, Bright GM, Isaacson RE, Newborg MF In vitro and in vivo uptake of azithromycin (CP-62,993) by phagocytic cells: possible mechanism of delivery and release a the site of infection. Antimicrobial Agents and Chemotherapy 1989, 33: 277–282.

    PubMed  Google Scholar 

  10. Girard AE, Girard D, English AR, Gootz TD, Cimochowski CR, Faiella JA, Haskell SL, Retsema JA Pharmacokinetic and in vivo studies with azithromycin (CP-62,993), a new macrolide with an extended half-life and excellent tissue distribution. Antimicrobial Agents and Chemotherapy 1987, 31: 1948–1954.

    PubMed  Google Scholar 

  11. Desmonts G, Remington JS Direct agglutination test for diagnosis of toxoplasma infection: method for increasing sensitivity and specificity. Journal of Clinical Microbiology 1980, 11: 562–564.

    PubMed  Google Scholar 

  12. Allegra CJ, Boarman D, Kovacs JA, Morrison P, Beaver J, Chabner B, Masur H Interaction of sulfonamide and sulfone compounds withToxoplasma gondii dihydropteroate synthase. Journal of Clinical Investigation 1990, 85: 371–379.

    PubMed  Google Scholar 

  13. Zhang Y, Meshnick SR Inhibition ofPlasmodium falciparum dihydropteroate synthetase and growth in vitro by sulfa drugs. Antimicrobial Agents and Chemotherapy 1991, 35: 267–271.

    PubMed  Google Scholar 

  14. Eyles DE, Coleman N An evaluation of the curative effects of pyrimethamine and sulfadiazine, alone and in combination, on experimental mouse toxoplasmosis. Antibiotics and Chemotherapy 1957, 5: 529–539.

    Google Scholar 

  15. Brooks RG, Remington JS, Luft BJ Drugs used in the treatment of toxoplasmosis. In: Peterson PK, Verhoef J (ed): The antimicrobial agents annual. Volume 2. Elsevier, Amsterdam, 1987, p. 297–306.

    Google Scholar 

  16. Israelski DM, Remington JS Toxoplasmic encephalitis in patients with AIDS. Infectious Disease Clinics of North America 1988, 2: 429–445.

    PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Research Institute, Palo Alto Medical Foundation, 860 Bryant St., 94301, Palo Alto, California, USA

    F. G. Araujo, T. Lin & J. S. Remington

  2. Division of Infectious Diseases, Department of Medicine, Stanford University School of Medicine, 94305, Stanford, California, USA

    J. S. Remington

Authors
  1. F. G. Araujo
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. T. Lin
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. J. S. Remington
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Araujo, F.G., Lin, T. & Remington, J.S. Synergistic combination of azithromycin and sulfadiazine for treatment of toxoplasmosis in mice. Eur. J. Clin. Microbiol. Infect. Dis. 11, 71–73 (1992). https://doi.org/10.1007/BF01971278

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF01971278

Keywords

Search

Navigation